secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0001213900-22-082228
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma reports FY2022 net loss $33.6M; cash $41.7M, I/ONTAK PDUFA July 2023
--------------------------------------------------------------------------------

- Net loss $33.6M ($0.23/shr) vs $23.1M ($0.23/shr) prior year; R&D expenses up $5.5M to $17.7M.
- Cash and equivalents $41.7M as of Sept 30, 2022; estimated runway through December 2023.
- I/ONTAK BLA accepted by FDA; PDUFA target action date set for July 28, 2023.
- Mino-Lok Phase 3: 169 patients enrolled, 72 of 92 failure events achieved, 17 patients pending.
- Halo-Lido Phase 2b enrollment ongoing; data readout expected in second half 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390022082228/0001213900-22-082228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390022082228/ea170685-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-082228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer